Kezar Life Sciences Inc (KZR)

$0.705

-0.02

(-3.24%)

Market is closed - opens 7 PM, 28 May 2024

Insights on Kezar Life Sciences Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 67.0% return, outperforming this stock by 142.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 238.7% return, outperforming this stock by 326.3%

Performance

  • $0.71
    $0.74
    $0.71
    downward going graph

    0.7%

    Downside

    Day's Volatility :5.25%

    Upside

    4.57%

    downward going graph
  • $0.67
    $3.13
    $0.71
    downward going graph

    4.99%

    Downside

    52 Weeks Volatility :78.45%

    Upside

    77.32%

    downward going graph

Returns

PeriodKezar Life Sciences IncSector (Health Care)Index (Russel 2000)
3 Months
-21.33%
-1.8%
0.0%
6 Months
-21.05%
10.1%
0.0%
1 Year
-75.35%
13.2%
0.0%
3 Years
-87.59%
17.0%
-21.4%

Highlights

Market Capitalization
53.0M
Book Value
$2.32
Earnings Per Share (EPS)
-1.39
Wall Street Target Price
11.67
Profit Margin
0.0%
Operating Margin TTM
-1491.77%
Return On Assets TTM
-27.01%
Return On Equity TTM
-48.07%
Revenue TTM
7.0M
Revenue Per Share TTM
0.1
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-103.4M
Diluted Eps TTM
-1.39
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.25
EPS Estimate Next Year
-1.18
EPS Estimate Current Quarter
-0.33
EPS Estimate Next Quarter
-0.33

Analyst Recommendation

Buy
    60%Buy
    40%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Kezar Life Sciences Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
7
8
Hold
4
3
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1555.32%

Current $0.71
Target $11.67

Technicals Summary

Sell

Neutral

Buy

Kezar Life Sciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kezar Life Sciences Inc
Kezar Life Sciences Inc
-12.41%
-21.05%
-75.35%
-87.59%
-92.88%
Moderna, Inc.
Moderna, Inc.
54.31%
114.37%
31.98%
-5.11%
673.49%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
11.53%
23.42%
35.86%
98.13%
219.88%
Novo Nordisk A/s
Novo Nordisk A/s
7.24%
30.97%
66.95%
238.66%
467.54%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
14.96%
30.49%
38.47%
120.96%
164.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kezar Life Sciences Inc
Kezar Life Sciences Inc
NA
NA
NA
-1.25
-0.48
-0.27
NA
2.32
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.6
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.99
28.99
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.75
46.75
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.23
29.23
0.53
17.14
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kezar Life Sciences Inc
Kezar Life Sciences Inc
Buy
$53.0M
-92.88%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$63.9B
673.49%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
219.88%
28.99
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$605.7B
467.54%
46.75
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.3B
164.5%
29.23
39.46%

Institutional Holdings

  • Suvretta Capital Management, LLC

    9.85%
  • Avidity Partners Management LP

    6.90%
  • BlackRock Inc

    6.62%
  • Prosight Management, LP

    4.62%
  • Vanguard Group Inc

    4.25%
  • Sphera Funds Management Ltd.

    2.82%

Company Information

kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.

Organization
Kezar Life Sciences Inc
Employees
58
CEO
Dr. Christopher J. Kirk Ph.D.
Industry
Health Technology

FAQs